Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

[ 18 f] trifluoromethyl sulfur-containing amino acid pet imaging agent and its preparation method and application

A technique of a trifluoro methyl -containing sulfur amino acid and a PET visually applied in the direction of sulfur ether preparation, pharmaceutical formula, in vivo radioactive preparations, etc., which can solve the poor nature of PET appearance quality, external stability or pharmacokinetic properties. Such problems, achieve the effect of good pharmacokinetics, accurate and malignant identification, and high tumor extraction rate

Active Publication Date: 2021-08-03
GUANGDONG HUIXUAN PHARMA TECH
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

but currently some 18 F-labeled sulfur-containing amino acid imaging agent has the disadvantages of poor in vivo and in vitro stability or poor pharmacokinetic properties after a large change in the molecular space structure, which affects its PET imaging quality

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • [ <sup>18</sup> f] trifluoromethyl sulfur-containing amino acid pet imaging agent and its preparation method and application
  • [ <sup>18</sup> f] trifluoromethyl sulfur-containing amino acid pet imaging agent and its preparation method and application
  • [ <sup>18</sup> f] trifluoromethyl sulfur-containing amino acid pet imaging agent and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The synthesis of embodiment 1 S-trifluoromethyl-L-cysteine

[0045] synthetic route:

[0046]

[0047] Precursor compound (4S)-1,2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylate tert-butyl ester References J. Med. Chem. 2010, 53, 876 –886 and Chemistry, 2018, https: / / doi.org / 10.1002 / chem.201801029 for synthesis, 1 H NMR (400 MHz, CDCl 3 ) δ 4.74 (t, 1H), 4.63 (d, 2H), 1.56 (s, 9H), 1.51 (s, 9H).

[0048] Synthetic steps:

[0049] (1) Add 194 mg of (4S)-1,2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylic acid tert-butyl ester to a 20 mL reaction flask in sequence, (three Phenylphosphonium) inner salt of difluoroacetic acid (PDFA) 427.6 mg, sulfur (S 8 ) 115.2 mg, cesium fluoride (CsF) 455.7 mg and anhydrous N,N-dimethylformamide (DMF) 4.5 mL, heated to 70 ℃ under the protection of argon, and reacted for 20 minutes.

[0050] (2) After the reaction was cooled, the reaction solution was transferred to a 100 mL reaction flask, and 20 mL of ethyl acetate and 10% sodi...

Embodiment 2

[0053] Example 2 [ 18 F] trifluoromethyl- L - Radiosynthesis of cysteine

[0054] synthetic route:

[0055]

[0056] Synthetic steps:

[0057] (1) In a cyclotron, by 18 O(p, n) 18 F nuclear reaction produces 18 f - ions, which are captured by the QMA column and delivered by the accelerator 18 f - ions, using K 2.2.2 / K 2 CO 3 The solution will 18 f - The ions are eluted to the reaction bottle; among them, K 2.2.2 / K 2 CO 3 The solution is 0.1 mL of 3.0 mg K 2 CO 3 aqueous solution, with 0.9 mL of 12mg K 2.2.2 Mixed solution of acetonitrile solution.

[0058] (2) Heat the reaction bottle to 95°C, remove the solvent under the condition of 80 mL / min nitrogen flow, and obtain the dry K 2.2.2 / K 18 F complex, then add anhydrous acetonitrile, get K after dissolving 2.2.2 / K 18 F complex acetonitrile solution, spare.

[0059] (3) 2 mg of tert-butyl (4S)-1,2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylate was prepacked in the fluorination reaction bottle, (t...

Embodiment 3

[0062] The synthesis of embodiment 3 S-trifluoromethyl-D-cysteine

[0063] synthetic route:

[0064]

[0065] Precursor compound (4R)-1,2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylate tert-butyl ester References J. Med. Chem. 2010, 53, 876 –886 and Chemistry, 2018, https: / / doi.org / 10.1002 / chem.201801029 for synthesis, 1 H NMR (400 MHz, CDCl3) δ 4.76 – 4.71 (m), 4.67 – 4.60 (m), 1.56 (s), 1.51 (s).

[0066] Synthetic steps:

[0067] The precursor compound of Example 1 was replaced by (4S)-1,2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylate tert-butyl ester with (4R)-1 , 2,3-oxathiazolidine-2,2-dioxide-3,4-dicarboxylic acid tert-butyl ester, the rest of the synthesis steps are the same as in Example 1, and finally S-trifluoromethyl- D - Cysteine. 1 H NMR (600 MHz, D 2 O) δ 4.00(dd, 1H), 3.55 (dd, 1H), 3.39 (dd, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Based on the principle of bioelectronic isosteric replacement, the present invention provides [ 18 F] trifluoromethyl sulfur-containing amino acid PET imaging agent, the PET imaging agent is [ 18 F] Trifluoromethyl‑ L ‑cysteine ​​or [ 18 F] Trifluoromethyl‑ D ‑cysteine; PET imaging agent can also be [ 18 F] Trifluoromethyl‑ L ‑Methionine or [ 18 F] Trifluoromethyl‑ D ‑Methionine. The PET imaging agent has high uptake in tumor tissue and low uptake in normal tissues and organs, and has good tumor specificity; and has high stability in vivo and in vitro, showing good pharmacokinetic properties. The present invention also provides this [ 18 F] Preparation method of trifluoromethyl sulfur-containing amino acid PET imaging agent and its application in tumor diagnosis and curative effect detection.

Description

technical field [0001] The present invention relates to the technical field of preparing positron emission tomography imaging agent, especially relates to [ 18 F] trifluoromethyl sulfur-containing amino acid PET imaging agent and its preparation method and application. Background technique [0002] 2-[ 18 F] fluorodeoxyglucose ( 18 F-FDG) is currently the most common glucose metabolism imaging agent in clinical positron emission tomography (PET) imaging. It has been widely used in lesion detection and other aspects. but 18 F-FDG also has disadvantages such as poor specificity, low uptake in some tumors, and high uptake in inflammatory tissues, which may cause false positive or false negative results in tumor PET imaging. [0003] The increase in the proliferation rate of malignant tumor cells will not only increase the translocation of amino acids, but also increase the rate of incorporation of amino acids into proteins in tumor cells. Therefore, amino acid PET imaging...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K51/04C07C323/58C07C319/20
CPCA61K51/0406C07C323/58
Inventor 唐刚华刘少玉
Owner GUANGDONG HUIXUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com